Picture of Open Access badges

Discover Open Access research at Strathprints

It's International Open Access Week, 24-30 October 2016. This year's theme is "Open in Action" and is all about taking meaningful steps towards opening up research and scholarship. The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs. Explore recent world leading Open Access research content by University of Strathclyde researchers and see how Strathclyde researchers are committing to putting "Open in Action".


Image: h_pampel, CC-BY

A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo

Bell, Helen S. and Dufès, Christine and O'Prey, Jim and Crighton, Diane and Bergamaschi, Daniele and Lu, Xin and Schätzlein, Andreas G. and Vousden, Karen H. and Ryan, Kevin M. (2007) A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. Journal of Clinical Investigation, 117 (4). pp. 1008-1018. ISSN 0021-9738

PDF (Bell 2007)
Belletal2007.pdf - Final Published Version

Download (939kB) | Preview


The tumor suppressor p53 is a potent inducer of tumor cell death, and strategies exist to exploit p53 for therapeutic gain. However, because about half of human cancers contain mutant p53, application of these strategies is restricted. p53 family members, in particular p73, are in many ways functional paralogs of p53, but are rarely mutated in cancer. Methods for specific activation of p73, however, remain to be elucidated. We describe here a minimal p53-derived apoptotic peptide that induced death in multiple cell types regardless of p53 status. While unable to activate gene expression directly, this peptide retained the capacity to bind iASPP - a common negative regulator of p53 family members. Concordantly, in p53-null cells, this peptide derepressed p73, causing p73-mediated gene activation and death. Moreover, systemic nanoparticle delivery of a transgene expressing this peptide caused tumor regression in vivo via p73. This study therefore heralds what we believe to be the first strategy to directly and selectively activate p73 therapeutically and may lead to the development of broadly applicable agents for the treatment of malignant disease.